← All FDA warning letters

FDA Warning Letter · #721600

Mile High Compounds LLC — FDA Warning Letter (March 31, 2026)

Issued March 31, 2026Status: activeCenter for Drug Evaluation and Research (CDER)

In plain English

Online sale of unapproved drugs

FDA said Mile High Compounds LLC offered semaglutide and tirzepatide products to U.S. consumers online that the agency considers unapproved and misbranded drugs.

What it means for you

Drugs sold this way have not been reviewed by FDA for safety, quality, or effectiveness. Fill a GLP-1 prescription only through a state-licensed pharmacy.

Drugs named:semaglutidetirzepatide

Primary Source

View the original FDA letter on fda.gov →

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mile-high-compounds-llc-721600-03312026

Letter details

Company
Mile High Compounds LLC
Letter number
#721600
Issue date
March 31, 2026
Subject
Unapproved New Drugs Sold Over the Internet

What FDA warning letters mean

A warning letter is FDA's principal means of telling a company that the agency considers something it's doing — a marketing claim, a manufacturing practice, a labeling choice — to violate the Federal Food, Drug, and Cosmetic Act. Companies typically have 15 working days to respond.

A warning letter is not a recall, a criminal charge, or a finding that the company has broken the law. It is the start of a regulatory conversation. FDA may issue a close-out letter once it is satisfied that the company has corrected the cited issues.

For compounded GLP-1 telehealth providers, the most common citations involve unapproved new drug claims, misbranding, and the use of bulk drug substances not on FDA's approved list under FDCA sections 503A and 503B.

What this letter means if you use compounded GLP-1s

A warning letter is not a recall, and it does not by itself mean a product you already have is unsafe, but it does mean the FDA found problems it expects Mile High Compounds LLC to fix. Compounded GLP-1s are not FDA-approved, and the rules for selling them changed when the shortages ended; our explainer on where compounded semaglutide stands with the FDA now covers what is still allowed.

This letter concerns drugs offered for sale online, so the first check is whether a seller is a licensed pharmacy at all. Our guide to spotting counterfeit semaglutide covers the warning signs, and the semaglutide page and tirzepatide page list the FDA-approved brands.

Other warning letters in our database

View the full database →

Editorial Disclaimer

FDA warning letters are public regulatory communications and do not, on their own, indicate that a company has done anything illegal. Companies often respond to warning letters with corrective action, and many letters are eventually closed out. The full text of this letter is available on fda.gov via the link above.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.